SOPHTY: Post-SOPHrology Cancer Patients' anxieTY Report
Study Details
Study Description
Brief Summary
Cancer is pathology with a high impact on patients and relatives quality of life. Most of the time, it is a stressful trial. Professionals have often resort to pharmaceutical solutions, but sometimes, it is not sufficient. So, patients resort to alternative and complementary medicines, as sophrology. In Lucien Neuwirth Cancer Institute, patients can benefit from sophrology.
Anxiety levels have never been reported before and after sessions. Indeed, the present study wants to report anxiety levels before, after, and one and three weeks after session. Levels of satisfaction will also be reported.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Cancer is pathology with a high impact on patients and relatives quality of life. Most of the time, it is a stressful trial. Professionals have often resort to pharmaceutical solutions, but sometimes, it is not sufficient. So, patients resort to alternative and complementary medicines, as sophrology. In Lucien Neuwirth Cancer Institute, patients can benefit from sophrology.
Anxiety levels have never been reported before and after sessions. Indeed, the present study wants to report anxiety levels before, after, and one and three weeks after session. Levels of satisfaction will also be reported.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cancer patients performing sophrology sessions Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale. |
Other: Questionnaires
Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
|
Outcome Measures
Primary Outcome Measures
- Level of anxiety difference [1 hour]
Level of anxiety after sophrology session will be compared to the level of anxiety before session, on a visual scale from 0 to 10. The scale is 10 centimeters long, printed on a paper.
Secondary Outcome Measures
- Level of anxiety difference [1 month]
Level of anxiety after a second session of sophrology will be compared to the level of anxiety reported before the first sophrology session, according to the Hospital Anxiety and Depression scale, part A. The part A is composed of seven questions, with a score obtained between 0 and 28. A score between : 7 or less : no symptomatology ; 8 to 10 : doubtful symptomatology ; 11 and more : certain symptomatology.
- Level of depression difference [1 month]
Level of depression after a second session of sophrology will be compared to the level of depression reported before the first sophrology session, according to the Hospital Anxiety and Depression scale, part B. The part B is composed of seven questions, with a score obtained between 0 and 28. A score between : 7 or less : no symptomatology ; 8 to 10 : doubtful symptomatology ; 11 and more : certain symptomatology.
- Sessions duration [1 hour]
Duration of sessions will be reported, unit used: minutes.
- Number of sessions [1 month]
Number of sessions performed during one month will be reported.
- Patients satisfaction [1 month]
Patients satisfaction will be reported during one month, as many times as they performed sophrology sessions, on a visual scale from 0 to 10. The scale is 10 centimeters long, printed on a paper.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patient performing at least one session of sophrology in the Lucien Neuwirth Cancer Institute
Exclusion Criteria:
-
Protected patient (according to the law),
-
Patient with incapacity to complete questionnaires,
-
Patient with incapacity to perform sophrologic movements.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut de Cancérologie Lucien Neuwirth | Saint-Priest-en-Jarez | France | 42270 |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Saint Etienne
- Institut de Cancérologie de la Loire
Investigators
- Principal Investigator: Stéphanie Morisson, MD, Institut de Cancérologie Lucien Neuwirth
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2018-0203
- 2018-A02004-51